Chromocell Therapeutics Files 8-K

Ticker: PTHS · Form: 8-K · Filed: 2024-03-13T00:00:00.000Z

Sentiment: neutral

Topics: reporting, sec-filing

TL;DR

Chromocell filed a routine 8-K, no major news.

AI Summary

Chromocell Therapeutics Corp. filed an 8-K on March 13, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates standard corporate reporting activity for Chromocell Therapeutics Corp. and does not disclose new material information that would immediately impact its stock.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain any new material information that would suggest increased risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.

What is the exact name of the registrant?

The exact name of the registrant is Chromocell Therapeutics Corporation.

In which state was Chromocell Therapeutics Corporation incorporated?

Chromocell Therapeutics Corporation was incorporated in Delaware.

What is the SEC file number for this filing?

The SEC file number for this filing is 001-41964.

What is the principal executive office address of the registrant?

The principal executive office address of the registrant is 4400 Route 9 South, Suite 1000, Freehold, NJ 07728.

Filing Stats: 1,000 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2024-03-13 08:00:48

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure . On March 13, 2023, Chromocell Therapeutics Corporation (the "Company") will present at the virtual Sidoti Small Cap Conference held by Sidoti Events, LLC to prospective investors, analysts, industry participants and other attendees, which can be accessed live at Sidoti Events, LLC's website. At the conference, the Company will provide an update on its product pipeline and discuss recent business developments, including its intended dose titration and Phase 2a clinical trials for systemic chronic pain and its pre-clinical trials for acute and chronic eye pain, both based on its proprietary compound, CC8464, and sublingual and intranasal programs under the exclusive licensing agreement with Benuvia Operations, LLC . The presentation materials furnished herewith as Exhibit 99.1 (the "Presentation Materials") were used in connection with such presentation, are incorporated into this Item 7.01 by reference and will be posted on the Company's website at https://www.chromocell.com. Information contained on the Company's website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K (this "Form 8-K"). The information contained in this Form 8-K under Item 7.01, including Exhibit 99.1 attached hereto, is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Form 8-K in such filing. The information set forth in this Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed an admission as to the materiality of any information in this Form 8-K that is required to be disclosed solely to s

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Chromocell Therapeutics Corporation March 2024 Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 13, 2024 CHROMOCELL THERAPEUTICS CORPORATION By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer

View on Read The Filing